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Abstract
Purpose—GOG 152 was a randomized trial of secondary cytoreductive surgery (SCS) in patients 
with suboptimal residual disease (residual tumor nodule >1 cm in greatest diameter) following 
primary cytoreductive surgery for advanced stage ovarian cancer. The current analysis was 
undertaken to evaluate the impact of disease findings at SCS on progression-free survival (PFS) 
and overall survival (OS).
Methods—Among the 550 patients enrolled on GOG-152, two-hundred-sixteen patients were 
randomly assigned following 3 cycles of cisplatin and paclitaxel to receive SCS. In 15 patients 
(7%) surgery was declined or contraindicated. In the remaining 201 patients the operative and 
pathology reports were utilized to classify their disease status at the beginning of SCS as; no gross 
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disease/microscopically negative N= 40 (19.9%), no gross disease/microscopically positive N= 8 
(4.0%), and gross disease N=153 (76.1%).
Results—The median PFS for patients with no gross disease/microscopically negative was 16.1 
months, no gross disease/microscopically positive was 13.5 months and for gross disease was 11.7 
months, p=0.002. The median OS for patients with no gross disease/microscopically negative was 
51.5 months, no gross disease/microscopically positive was 42.6 months and for gross disease was 
34.9 months, p=0.018.
Conclusion—Although as previously reported SCS did not change PFS or OS, for those who 
underwent the procedure, their operative and pathologic findings were predictive of PFS and OS. 
Surgical/pathological residual disease is a biomarker of response to chemotherapy and predictive 
of PFS and OS.
Keywords
Pathologic complete response; secondary cytoreduction
INTRODUCTION
The approval of new oncology therapeutics is time intensive and ultimately requires a phase 
III randomized trial testing a new regimen against standard therapy [1]. However, years of 
preclinical and early clinical trial development are required before a Phase III randomized 
trial can commence. Additionally, the conduct of a Phase III randomized trial is lengthy and 
includes; patient recruitment, completion of a therapeutic intervention and close observation 
for clinical events. For certain cancers with a long median survival, such as breast or ovarian 
cancer, years of observation are often necessary for event outcomes (progression and death) 
to occur. While the current drug approval “identity to registration” paradigm is effective, 
collectively, the approval of a new oncology therapeutic may take a decade or more.
A surrogate endpoint of survival that could be identified early in the course of disease 
treatment could potentially shorten approval of new oncology therapeutics. A pathologic 
complete response has been identified as a biomarker of response to chemotherapy and is 
predictive of progression-free survival (PFS) and overall survival (OS) in multiple tumor 
types [2,3,4]. In breast cancer, pathologic complete response following neoadjuvant 
chemotherapy has been utilized for “accelerated” approval of pertuzumab although final 
survival will still need to be demonstrated for “regular” approval [5]. The benefit of 
accelerated approval is that it allows earlier availability of therapeutic agents for cancer 
patients. In ovarian cancer data regarding pathologic complete response (CR) rates following 
induction chemotherapy are lacking. In a large Italian retrospective multicenter study of 322 
patients treated with neoadjuvant chemotherapy and interval debulking surgery the 
pathologic CR was 6.5% [6]. For patients with a pathologic CR the median PFS was 36 
month and median OS was 72 months, compared to PFS and OS of 16 months and 38 
months for microscopic partial response (PR) and 13 months and 29 months for macroscopic 
PR patients. However, the number of the courses of chemotherapy before interval debulking 
surgery varied from 4 to 6 and the regimens utilized varied but were all carboplatin based. 
More recently the results of the Chorus trial have been presented with 4% of the patients 
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undergoing 3 cycles of platinum-based chemotherapy and interval debulking surgery having 
no evidence of residual disease.[7] However, the outcome of this patient population has not 
been defined.
The amount of residual disease following primary debulking surgery is associated with PFS 
and OS [8]. Hoskins and McGuire evaluating Gynecologic Oncology Group (GOG) data 
established the optimal residual disease diameter as 1 cm or less and suboptimal as more 
than 1 cm [9]. In an effort to optimize residual disease secondary cytoreductive surgery has 
been used in patients who have undergone suboptimal primary surgery. GOG-152 was a 
randomized trial evaluating the utility of secondary cytoreductive surgery for patients with 
suboptimal primary debulking following 3 cycles of chemotherapy with cisplatin and 
paclitaxel [10]. This trial, which was previously reported, demonstrated no improvement for 
patients who underwent secondary cytoreductive surgery. The purpose of the current study 
was to evaluate the association between surgical pathologic findings of patients who 
underwent secondary cytoreductive surgery (SCS) and survival outcomes.
METHODS
The methodology for this study has previously been published in detail [9]. Briefly, from 
June 1994 through January 2001, 550 patients who had advanced ovarian cancer and 
residual tumor exceeding 1 cm in diameter after primary surgery, were enrolled and 424 
eligible were randomized; 216 to chemotherapy plus SCS and 208 to chemotherapy alone. In 
15 patients (7%) randomized to SCS, surgery was declined or contraindicated. The 
remaining 201 patients who received chemotherapy and SCS are the subject of this study. 
All patients had surgical report forms which documented at least 55 potential sites of 
residual intra-abdominal disease following their primary and secondary cytoreductive 
procedures. Secondary cytoreductive surgery was prescribed to be performed after the third 
course of chemotherapy as soon as nadir counts permitted but must have been performed 
within 6 weeks of the third course of chemotherapy. Secondary cytoreductive surgery 
involved an abdominal incision adequate to explore the entire abdominal cavity. All 
peritoneal surfaces including the undersurface of both diaphragms and the serosa and 
mesentery of the entire GI tract were to be visualized and palpated. Careful inspection and 
removal of at least the infracolic omentum was mandated as well as extra fascial 
hysterectomy and bilateral salpingo-oophorectomy if not performed at the primary 
cytoreductive procedure. All gross residual disease identified was to be resected.
Disease status at secondary cytoreductive surgery was evaluated by operative and pathologic 
reports. Patients disease status at the beginning of their SCS was classified as one of 3 
groups; pathologic CR: those having no gross residual disease and no microscopic disease, 
pathologic PR: those having no gross residual disease but microscopic disease, and gross 
disease: those having gross residual disease.
In the statistical analysis, categorical variables were compared between the patient 
subgroups by the Pearson chi-square test [11], and continuous variables by the Kruskal–
Wallis test [12]. Progression-free and overall survival was estimated using the Kaplan–Meier 
method [13], and differences between groups evaluated by the log-rank test. All statistical 
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tests were two-tailed with the significance level set at α=0.05. Statistical analyses were 
performed using the R programming language and environment [14].
RESULTS
As previously reported, the median time to progression or death (PFS) was 10.5 months in 
the SCS group and 10.7 months in the chemotherapy-alone group. Similarly, the median OS 
was 33.9 months in the SCS group and 33.7 months in the chemotherapy-alone group. The 
patient characteristics of the 201 patients underwent SCS are listed on Table 1. Ninety-four 
percent had a performance status of 0–1, 75% were serous histology and 93% were stage III 
with only 8.5% having grade 1 histology. Among the 201 patients who underwent SCS; 
76.1% had a gross PR, 4.0% had a pathologic PR, and 19.9% had a pathologic CR.(Table 2)
The median PFS for patients with a pathologic CR was 16.1 months, pathologic PR was 
13.5 months and for gross disease was 11.7 months, p=0.002.(Figure 1) The median OS for 
patients with a pathologic CR was 51.5 months, pathologic PR was 42.6 months and for 
gross disease was 34.9 months, p=0.018.(Figure 2)
A pathologic CR was not associated with stage, residual disease diameter, tumor histology 
or grade, age, baseline CA 125. (Table 3)
DISCUSSION
Surgical assessment of disease extent was first studied by Wangensteen et al in 
gastrointestinal cancer [15]. Surgical assessment of disease following treatment (second-
look laparotomy) was quickly adopted in ovarian cancer due to the toxicity of continued 
alkylating agent therapy and difficulty of confirming a complete responses to chemotherapy 
[16,17]. Second-Look laparotomy (SLL) became an NCI standard over 3 decades for 
evaluating patients in a complete clinical response following the completion of 
chemotherapy. In both GOG-104 and GOG-172 intraperitoneal therapy was associated with 
increased rates of negative SLL and corresponding increase in survival [18,19]. In 
GOG-158, a trial which established equivalence of two platinum compounds; cisplatin or 
carboplatin with paclitaxel, SLL was optional but had to be pre-assigned prior to 
randomization [20]. Second-look laparotomy was not randomly assigned and evaluating the 
role of SLL was not an objective of the study. However, in an exploratory date analysis, 
among the 792 patients in the trial 393 underwent SLL and 399 were observed, SLL resulted 
in a one month improvement in PFS which was non-significant and an identical OS. In view 
of the lack of benefit and potential for morbidity routine use of SLL was abandoned.
In our study patients with suboptimal disease following primary cytoreductive surgery who 
had a pathologic CR at secondary cytoreductive surgery had improved PFS and OS. The 
outcome of patients who achieved a pathologic PR was only marginally better than those 
with a gross PR both of which were significantly worse than a pathologic CR. This is 
consistent with our extensive experience with SLL and the Italian neoadjuvant trial [6,21]. 
Unfortunately, normal CA 125 values and CT or PET/CT imaging are necessary but not 
sufficient to ensure a pathologic complete response. Despite normal CA 125 values and 
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PET/CT scans 55% of patients with advanced stage ovarian cancer have persistent disease at 
SLL [22].
The use of neoadjuvant chemotherapy as a primary treatment strategy is increasing. At 
National Comprehensive Cancer Network institutions the use of neoadjuvant chemotherapy 
has increased and is being utilized in 53% of stage IIIC and 58% of stage IV patients [23]. 
However, primary debulking surgery has been the primary treatment paradigm utilized by 
the GOG since its inception. Only one protocol (GOG- 273), which was a protocol designed 
for elderly patients greater than 70 years of age, allowed neoadjuvant chemotherapy patients 
to be eligible.[24] This trial did not require interval debulking. Secondary cytoreductive 
surgery has only been studied in one GOG trial (GOG-152).[10] This allowed us to evaluate 
the pathologic CR rate following three cycles of chemotherapy. However, one GOG trial in 
optimal disease stage III patients (GOG-8812) utilized surgical reassessment after three 
cycles of chemotherapy with cisplatin and cyclophosphamide followed by hyperfractionated 
abdominal radiotherapy with a pathologic CR rate of 32% [25].
The pathologic complete response rates from induction chemotherapy in patients with 
optimal primary cytoreductive surgery, suboptimal primary cytoreductive surgery, and 
neoadjuvant chemotherapy were 32%, 20% and 6% and 4% respectively [25,10,6,7]. This 
suggests that the amount of residual disease prior to initiation of chemotherapy is related to 
the pathologic complete response rate. However, in the current study, tumor size was not 
related to pathologic CR. Similarly, in breast cancer tumor size has not predicted pathologic 
CR but molecular subgrouping did [26]. Molecular profiling has not been performed in the 
GOG, Chorus or Italian ovarian cancer studies previously discussed. In ovarian cancer, 
BRCA germ-line mutation identifies a sub group of patients with deficiencies in 
homologous re-combination DNA repair and improved response to chemotherapy and longer 
progression free and overall survival.[27] In a recent study of neoadjuvant chemotherapy in 
breast cancer, patients who had deficiencies in homologous re-combination DNA repair had 
a significantly higher rate of pathologicCR 58% versus 18%.[28] It is likely molecular 
profiling of ovarian cancer patients will identify a subgroup of patients who are more likely 
to have a complete pathologic response.
The strengths of this study include; uniform chemotherapy treatment and uniform timing of 
surgical disease reassessment. Additionally, this is a multi-centered prospective clinical trial 
with a large number of patients with longitudinal follow-up. However, weaknesses of this 
study include; the lack of genetic testing for germ-line BRCA and BRCAoid mutations and 
the lack of tumor profiling. The GOG did establish a prospective tumor protocol (GOG-136) 
in 1992, however only 11% of GOG-152 patients had banked tissue.
Based on the results of GOG-152, secondary cytoreductive surgery following suboptimal 
tumor resection by a gynecologic oncologist is not standard of care. But, the findings of this 
study are thought provoking and confirm the previously reported retrospective data 
following neoadjuvant chemotherapy where a pathologic complete response is associated 
with improved survival. Surgical intervention following neoadjuvant chemotherapy (interval 
debulking surgery) is an accepted treatment paradigm. Therefore, if the pathologic response 
rates following neoadjuvant can be confirmed, neoadjuvant chemotherapy followed by early 
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surgical reassessment may be a new platform for accelerated oncology therapeutic approval 
in ovarian cancer. Future NRG studies are evaluating novel agents in combination with 
platinum and taxane based regimens to see if the addition of novel therapeutic agents will 
increase of pathologic complete response and improve survival outcomes.
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Figure 1. 
Kaplan-Meier PFS by Residual Disease
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Figure 2. 
Kaplan-Meier OS by Residual Disease
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Table 1
Patient Characteristics
N
Age years 201 49.9 57.6 65.3
Performance status 201
 0 38.3% (77)
 1 55.7% (112)
 2 6.0% (12)
Histology 201
 serous 75.6% (152)
 mixed epithelial 9.5% (19)
 endometrioid 8.5% (17)
 other 6.5% (13)
Top-level FIGO stage 201
 III 92.5% (186)
 IV 7.5% (15)
Tumor grade (differentiation) 201
 Grade 1 8.5% (17)
 Grade 2 38.8% (78)
 Grade 3 52.2% (105)
 NA 0.5% (1)
Pre-study residual cm 193 10 15 20
Baseline CA-125 IU/ml 159 145 335 858
a b c represent the lower quartile a, the median b, and the upper quartile c for continuous variables.
N is the number of non–missing values. Numbers after percents are frequencies.
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Table 2
Findings at IDS; 201 patients
Findings Number (%)
Gross residual disease 153 (76.1%)
No gross residual disease but microscopic disease 8 (4.0%)
No gross residual disease and no microscopic disease. 40 (19.9%)
TOTAL 216 (100%)
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